Deals 30 September 2024 Regor’s selective approach attracts Roche For $850m up front Roche gets to challenge Pfizer. Read more
Conferences Trial results 15 September 2024 ESMO 2024 – combos could be the way forward for CDK2 Incyte’s first substantial data with INCB123667 are eclipsed by Pfizer’s PF-07104091/atirmociclib combo. Read more